Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer’s Disease (AD) and Age-Related Macular Degeneration (AMD)

Molecular Neurobiology

Volumn 52, Issue 1, 2015, Pages 533-544

  Zhao, Yuhai ^a   Bhattacharjee, Surjyadipta ^a   Jones, Brandon M ^a   Hill, James M ^a,b   Clement, Christian ^c   Sambamurti, Kumar ^d   Dua, Prerna ^e   Lukiw, Walter J ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SOUTHERN UNIVERSITY AT NEW ORLEANS   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

42 amino acid amyloid beta (A 42); Age related macular degeneration (AMD); Alzheimer s disease (AD); Beta amyloid precursor protein ( APP); CNS inflammation; Drusen; Micro RNA (miRNA); Neurological disease; sAPP ; Senile plaques; Transmissibility; APP processing

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; COMPLEMENT FACTOR H; GAMMA SECRETASE; MICRORNA; NEUROTOXIN; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; AMYLOIDOSIS; BIOACCUMULATION; BRAIN; COGNITIVE DEFECT; COMPLEX FORMATION; DISEASE ASSOCIATION; DISEASE MARKER; DRUSEN; ENVIRONMENTAL FACTOR; EPIGENETICS; GAIN OF FUNCTION MUTATION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MURINE MODEL; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PROTEIN METABOLISM; PROTEIN PROCESSING; RETINA; REVIEW; SENILE PLAQUE; ANIMAL; COMPLICATION; DISEASE MODEL; GENETIC EPIGENESIS; GENETICS; MACULAR DEGENERATION; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HUMANS; MACULAR DEGENERATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84937932912     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8886-3     Document Type: Review

References (110)

1. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends Cell Biol 8:447–453
2. Jellinger KA (2012) Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 16:1166–1183
3. Yang X, Sun GY, Eckert GP, Lee JC (2014) Cellular membrane fluidity in amyloid precursor protein processing. Mol Neurobiol. doi:10.1007/s12035-014-8652-6
4. Lukiw WJ (2013) Alzheimer’s disease (AD) as a disorder of the plasma membrane. Front Physiol 4:24. doi:10.3389/fphys.2013.00024
5. Dorey E, Chang N, Liu QY, Yang Z, Zhang W (2014) Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease. Neurosci Bull 30:317–330
6. Glenner GG, Henry JH, Fujihara S (1981) Congophilic angiopathy in the pathogenesis of Alzheimer’s degeneration. Ann Pathol 1:120–129
7. Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 425:534–539
8. Glenner GG, Murphy MA (1989) Amyloidosis of the nervous system. J Neurol Sci 94:1–28
9. Buda O, Arsene D, Ceausu M, Dermengiu D, Curca GC (2009) Georges Marinesco and the early research in neuropathology. Neurology 72:88–91
10. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin Anat 8:429–431
11. Armstrong RA (2008) Spatial correlations between beta-amyloid (Abeta) deposits and blood vessels in familial Alzheimer’s disease. Folia Neuropathol 46:241–248
12. Furumoto S, Okamura N, Iwata R, Yanai K, Arai H, Kudo Y (2007) Recent advances in the development of amyloid imaging agents. Curr Top Med Chem 7:1773–1789
13. Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med 42:423–432
14. Lengyel I, Tufail A, Hosaini HA, Luthert P, Bird AC, Jeffery G (2004) Association of drusen deposition with choroidal intercapillary pillars in the aging human eye. Invest Ophthalmol Vis Sci 45:2886–2892
15. Buschini E, Piras A, Nuzzi R, Vercelli A (2011) Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 95:14–25
16. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12:383–388
17. Nalivaeva NN, Turner AJ (2013) The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett 587:2046–2054
18. Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G (2014) The dark sides of amyloid in Alzheimer’s disease pathogenesis. FEBS Lett 588:641–652
19. Ohno-Matsui K (2011) Parallel findings in age-related macular degeneration and Alzheimer’s disease. Prog Retin Eye Res 30:217–238
20. Huang EJ, Wu SH, Lai CH, Kuo CN, Wu PL, Chen CL, Chen CY, King YC, Wu PC (2014) Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western Taiwan: the Puzih eye study. Eye (Lond). doi:10.1038/eye.2014.55
21. Moon BG, Joe SG, Hwang JU, Kim HK, Choe J, Yoon YH (2012) Prevalence and risk factors of early-stage age-related macular degeneration in patients examined at a health promotion center in Korea. J Korean Med Sci 27:537–541
22. Tharp WG, Sarkar IN (2013) Origins of amyloid-β. BMC Genomics 14:290. doi:10.1186/1471-2164-14-290
23. Chen Y, Tang BL (2006) The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. Biochem Biophys Res Commun 341:1–5
24. Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. Neuromol Med 12:1–12
25. Exley C (2005) The aluminum-amyloid cascade hypothesis of Alzheimer’s disease. Subcell Biochem 38:225–234
26. Walton JR (2013) Aluminum involvement in the progression of Alzheimer’s disease. J Alzheimers Dis 35:7–43
27. Kruck TP, Cui JG, Percy ME, Lukiw WJ (2004) Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum. Cell Mol Neurobiol 24:443–459
28. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 337:1304–1308
29. Percy ME, Kruck TP, Pogue AI, Lukiw WJ (2011) Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer’s disease. J Inorg Biochem 105:1505–1512
30. Bhattacharjee S, Zhao Y, Hill JM, Percy ME, Lukiw WJ (2014) Aluminum and its potential contribution to Alzheimer’s disease (AD). Front Aging Neurosci 6:62. doi:10.3389/fnagi.2014.00062.eCollection 2014
31. Alexandrov PN, Zhao Y, Jones BM, Bhattacharjee S, Lukiw WJ (2013) Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a. J Inorg Biochem 128:267–269
32. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH (2002) The Alzheimer’s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99:11830–11835
33. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J (2006) Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116:378–385
34. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL (2003) Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9:184–190
35. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV (2004) Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78:243–256
36. Prakasam A, Muthuswamy A, Ablonczy Z, Greig NH, Fauq A, Rao KJ, Pappolla MA, Sambamurti K (2010) Differential accumulation of secreted AbetaPP metabolites in ocular fluids. J Alzheimers Dis 20:1243–1253
37. Aruoma OI, Jen SS, Watts HR, George J, Gentleman SM, Anderson PJ, Jen LS (2009) Acute and chronic effects of intravitreally injected beta-amyloid on the neurotransmitter system in the retina. Toxicology 256:92–100
38. Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neumann H (2013) Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS ONE 8(1):e52982
39. Zhao Y, Bhattacharjee S, Jones BM, Dua P, Alexandrov PN, Hill JM, Lukiw WJ (2013) Regulation of TREM2 expression by an NF-кB-sensitive miRNA-34a. Neuroreport 24:318–323
40. Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J et al (2013) Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging 34:2699–2714
41. Hickman SE, El Khoury J (2014) TREM2 and the neuro-immunology of Alzheimer’s disease. Biochem Pharmacol 88:495–498
42. Yin RH, Yu JT, Tan L (2014) The role of SORL1 in Alzheimer’s disease. Mol Neurobiol. doi:10.1007/s12035-014-8742-5. PubMed PMID: 24833601
43. Cui JG, Hill JM, Zhao Y, Lukiw WJ (2007) Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer’s disease. Neuroreport 18:115–119
44. Waring SC, Rosenberg RN (2008) Genome-wide association studies in Alzheimer disease. Arch Neurol 65:329–334
45. Neumann H, Daly MJ (2013) Variant TREM2 as risk factor for Alzheimer’s disease. N Engl J Med 368:182–184
46. Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ (2011) Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport 22:623–627
47. Zhao Y, Lukiw WJ (2013) TREM2 signaling, miRNA-34a and the extinction of phagocytosis. Front Cell Neurosci 7:131–135
48. Hickman SE, El Khoury J (2013) TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol 88:495–498
49. Jones BM, Bhattacharjee S, Dua P, Hill JM, Zhao Y, Lukiw WJ (2014) Regulating amyloidogenesis through the natural triggering receptor expressed inmyeloid/microglial cells 2 (TREM2). Front Cell Neurosci 8:94
50. Jiang T, Yu JT, Zhu XC, Tan L (2013) TREM2 in Alzheimer’s disease. Mol Neurobiol 48:180–185
51. Dawkins E, Small DH (2014) Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer’s disease. J Neurochem 129:756–769
52. Lukiw WJ (2013) Antagonism of NF-κB-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer’s disease (AD): anti-NF-κB vs. anti-miRNA strategies. Front Genet 4:77–79
53. Lukiw WJ (2013) Variability in micro RNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to Alzheimer’s disease (AD). Front Cell Neurosci 7:133
54. Lukiw WJ (2012) Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD). Expert Opin Emerg Drugs. doi:10.1517/14728214.2012.672559. PubMed Central PMCID: PMC3399957
55. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (2006) Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 26:7212–7221
56. Tyan SH, Shih AY, Walsh JJ, Maruyama H, Sarsoza F, Ku L, Eggert S, Hof PR, Koo EH, Dickstein DL (2012) Amyloid precursor protein (APP) regulates synaptic structure and function. Mol Cell Neurosci 51:43–52
57. Hoe HS, Lee HK, Pak DT (2012) The upside of APP at synapses. CNS Neurosci Ther 18:47–56
58. Turner PR, O’Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70:1–32
59. Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, Williamson NA, White AR, Hinds MG, Norton RS, Beyreuther K, Masters CL, ParkerMW CR (2003) Structure of the Alzheimer’s disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 278:17401–17407
60. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI (2010) Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 142:857–867
61. Porayette P, Gallego MJ, Kaltcheva MM, Meethal SV, Atwood CS (2007) Amyloid-beta precursor protein expression and modulation in human embryonic stem cells: a novel role for human chorionic gonadotropin. Biochem Biophys Res Commun 364:522–527
62. Sheng B, Song B, Zheng Z, Zhou F, Lu G, Zhao N, Zhang X, Gong Y (2009) Abnormal cleavage of APP impairs its functions in cell adhesion and migration. Neurosci Lett 450:327–331
63. Wang Z, Yang L, Zheng H (2012) Role of APP and Aβ in synaptic physiology. Curr Alzheimer Res 9:217–226
64. Allsop D, Ikeda S, Glenner GG (1989) Evidence for the derivation of a peptide ligand from the amyloid beta-protein precursor of Alzheimer’s disease. Prog Clin Biol Res 317:893–902
65. Mattson MP (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77:1081–1132
66. Satpute-Krishnan P, Degiorgis JA, Conley MP, Jang M, Bearer EL (2006) A peptide zipcode sufficient for anterograde transport within amyloid precursor protein. Proc Natl Acad Sci 103:16532
67. Swomley AM, Förster S, Keeney JT, Triplett J, Zhang Z, Sultana R, Butterfield DA (2013) Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta 1842:1248–1257
68. Rossjohn J, Cappai R, Feil SC, Henry A, McKinstry WJ, Galatis D, Hesse L, Multhaup G, Beyreuther K, Masters CL, Parker MW (1999) Crystal structure of theN-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol 6:327–331
69. Goldstein LS (2001) Kinesin molecular motors: transport pathways, receptors, and human disease. Proc Natl Acad Sci U S A 98:6999–7003
70. Taru H, Suzuki T (2009) Regulation of the physiological function and metabolism of AbetaPP by AbetaPP binding proteins. J Alzheimers Dis 18:253–265
71. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, Hashemi M, Owji AA, Łos MJ (2014) Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 112:24–49
72. Müller T, Schrötter A, Loosse C, Pfeiffer K, Theiss C, Kauth M, Meyer HE, Marcus K (2013) A ternary complex consisting of AICD, FE65, and TIP60 down-regulates stathmin1. Biochim Biophys Acta 1834:387–394
73. Li YY, Cui JG, Dua P, Pogue AI, Bhattacharjee S, Lukiw WJ (2011) Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells. Neurosci Lett 499:109–113
74. Lukiw WJ (2012) NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells. Exp Neurol 235:484–490
75. Cui JG, Fraser PE, St George-Hyslop P, Westaway D, Lukiw WJ (2004) Potential roles for presenilin-1 in oxygen sensing and in glial-specific gene expression. Neuroreport 15:2025–2028
76. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG (2011) Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease models. PLoS ONE 6:e15816
77. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT (2013) Complement factor H related proteins (CFHRs). Mol Immunol 56:170–180
78. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A (2014) Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. doi:10.1146/annurev-genom-090413-025610. PubMed PMID: 24773320
79. Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H (2008) Association of complement factor H Y402H gene polymorphism with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147:720–726
80. Le Fur I, Laumet G, Richard F, Fievet N, Berr C, Rouaud O, Delcourt C, Amouyel P, Lambert JC (2010) Association study of the CFH Y402H polymorphism with Alzheimer’s disease. Neurobiol Aging 31:165–166
81. Proitsi P, Lupton MK, Dudbridge F, Tsolaki M, Hamilton G, Daniilidou M, Pritchard M, Lord K, Martin BM, Johnson J, Craig D, Todd S, McGuinness B, Hollingworth P, Harold D, Kloszewska I, Soininen H, Mecocci P, Velas B, Gill M, Lawlor B, Rubinsztein DC, Brayne C, Passmore PA, Williams J, Lovestone S, Powell JF (2012) Alzheimer’s disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiol Aging 33:1843.e9–1843.e17. doi:10.1016/j.neurobiolaging.2011.12.036
82. Liu MM, Chan CC, Tuo J (2012) Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics. Hum Genomics 6:13. doi:10.1186/1479-7364-6-13
83. Lukiw WJ, Zhao Y, Cui JG (2008) An NF-kB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283:31315–31322
84. Lukiw WJ, Alexandrov PN (2012) Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer’s disease (AD) brain. Mol Neurobiol 46:11–19
85. Ambros V (2001) microRNAs: tiny regulators with great potential. Cell 107:823–826
86. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294:853–858
87. Alexandrov PN, Dua P, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ (2012) microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 3:365–373
88. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835–840
89. Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN (2012) Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer’s disease (AD) and in age-related macular degeneration (AMD). Int J Biochem Mol Biol 3:105–116
90. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29:95–112
91. Quan YL, Zhou AY, Feng ZH (2012) Association between complementary factor H Y402H polymorphisms and age-related macular degeneration in Chinese: systematic review and meta-analysis. Int J Ophthalmol 5:242–246
92. Kondo N, Bessho H, Honda S, Negi A (2011) Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 118:339–344
93. Ermilov VV, Tiurenkov IN, Nesterova AA, Zagrebin VA (2013) Alzheimer’s disease and geriatric eye diseases in the aspect of amyloid genesis. Arkh Patol 75:37–42
94. Frost S, Kanagasingam Y, Sohrabi H, Vignarajan J, Bourgeat P, Salvado O, Villemagne V, Rowe CC, Macaulay SL, Szoeke C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN, Group AR (2013) Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl Psychiatry 3:e233
95. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG, Hollyfield JG (2002) Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 99:14682–14687
96. Jiang T, Yu JT, Zhu XC, Tan MS, Gu LZ, Zhang YD et al (2014) Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 35:1243–1251
97. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman C, Golde T, Grant MB, Saftig P, Serneels L, de Strooper B, Joussen AM, Boulton ME (2012) beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 4:980–991
98. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318
99. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE (2013) Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78:631–643
100. Sivak JM (2013) The aging eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Invest Ophthalmol Vis Sci 54:871–880
101. Baker ML, Wang JJ, Rogers S, Klein R, Kuller LH, Larsen EK, Wong TY (2009) Early age-related macular degeneration, cognitive function, and dementia: the Cardiovascular Health Study. Arch Ophthalmol 127:667–673
102. Woo SJ, Park KH, Ahn J, Choe JY, Jeong H, Han JW, Kim TH, Kim KW (2012) Cognitive impairment in age-related macular degeneration and geographic atrophy. Ophthalmology 119:2094–2101
103. Raj A, Rifkin SA, Andersen E, van Oudenaarden A (2010) Variability in gene expression underlies incomplete penetrance. Nature 463:913–918
104. Chiu K, Chan TF, Wu A, Leung IY, So KF, Chang RC (2012) Neurodegeneration of the retina in mouse models of Alzheimer’s disease: what can we learn from the retina? Age (Dordr) 34:633–649
105. Logue MW, Schu M, Vardarajan BN, Farrell J, Lunetta KL, Jun G, Baldwin CT, Deangelis MM, Farrer LA (2014) A search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiol Aging 35:1510.e7–1510.e18
106. Olson MV (2012) Human genetic individuality. Annu Rev Genomics Hum Genet 13:1–27
107. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C (2008) Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res 48:339–345
108. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, Harrabi O, Bollini SS, Dilley J, Kobayashi D, Kuang B, Li W, Pons J, Lin JC, Bowes Rickman C (2011) Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A 108:E279–E287
109. Hu N, Tan MS, Sun L, Jiang T, Wang YL, Tan L, Zhang W, Yu JT, Tan L (2014) Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer’s disease patients. Neurosci Lett 563:51–54
110. Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG (2009) Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease. Graefes Arch Clin Exp Ophthalmol 247:1213–1221